These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 28649246)

  • 1. Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an "Off-the-Shelf Immunotherapy" for Improvement in Cancer Treatment.
    Oberschmidt O; Kloess S; Koehl U
    Front Immunol; 2017; 8():654. PubMed ID: 28649246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
    Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
    J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity.
    Zhang C; Oberoi P; Oelsner S; Waldmann A; Lindner A; Tonn T; Wels WS
    Front Immunol; 2017; 8():533. PubMed ID: 28572802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.
    Hu Y; Tian ZG; Zhang C
    Acta Pharmacol Sin; 2018 Feb; 39(2):167-176. PubMed ID: 28880014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro.
    Huang Y; Zeng J; Liu T; Xu Q; Song X; Zeng J
    Cancer Manag Res; 2020; 12():3247-3255. PubMed ID: 32440221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TCR extracellular domain genetically linked to CD28, 2B4/41BB and DAP10/CD3ζ -engineered NK cells mediates antitumor effects.
    Li S; Zhang C; Shen L; Teng X; Xiao Y; Yu B; Lu Z
    Cancer Immunol Immunother; 2023 Mar; 72(3):769-774. PubMed ID: 35988132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
    Mehta RS; Rezvani K
    Front Immunol; 2018; 9():283. PubMed ID: 29497427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response.
    Hombach A; Hombach AA; Abken H
    Gene Ther; 2010 Oct; 17(10):1206-13. PubMed ID: 20555360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.
    Genßler S; Burger MC; Zhang C; Oelsner S; Mildenberger I; Wagner M; Steinbach JP; Wels WS
    Oncoimmunology; 2016 Apr; 5(4):e1119354. PubMed ID: 27141401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack.
    Chmielewski M; Hombach AA; Abken H
    Gene Ther; 2011 Jan; 18(1):62-72. PubMed ID: 20944680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric Receptor.
    Eisenberg V; Shamalov K; Meir S; Hoogi S; Sarkar R; Pinker S; Markel G; Porgador A; Cohen CJ
    Front Immunol; 2017; 8():1212. PubMed ID: 29085357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy.
    Fabian KP; Hodge JW
    Mol Ther Oncolytics; 2021 Dec; 23():266-276. PubMed ID: 34761106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilizing chimeric antigen receptors to direct natural killer cell activity.
    Hermanson DL; Kaufman DS
    Front Immunol; 2015; 6():195. PubMed ID: 25972867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein.
    Sautto GA; Wisskirchen K; Clementi N; Castelli M; Diotti RA; Graf J; Clementi M; Burioni R; Protzer U; Mancini N
    Gut; 2016 Mar; 65(3):512-23. PubMed ID: 25661083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential.
    Wang X; Yang X; Yuan X; Wang W; Wang Y
    Exp Hematol Oncol; 2022 Nov; 11(1):85. PubMed ID: 36324149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.
    Rezvani K; Rouce RH
    Front Immunol; 2015; 6():578. PubMed ID: 26635792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor-natural killer cells: Novel insight into immunotherapy for solid tumors (Review).
    Peng X; Chen L; Chen L; Wang B; Wang Y; Zhan X
    Exp Ther Med; 2021 Apr; 21(4):340. PubMed ID: 33732313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance.
    Caratelli S; Sconocchia T; Arriga R; Coppola A; Lanzilli G; Lauro D; Venditti A; Del Principe MI; Buccisano F; Maurillo L; Ferrone S; Sconocchia G
    Front Immunol; 2017; 8():457. PubMed ID: 28496440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.